News articles about Marinus Pharmaceuticals (NASDAQ:MRNS) have been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.2019578627606 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Marinus Pharmaceuticals (MRNS) traded down 1.96% during mid-day trading on Friday, reaching $3.00. The company’s stock had a trading volume of 434,029 shares. The firm’s market cap is $78.23 million. The stock’s 50 day moving average is $2.27 and its 200 day moving average is $1.62. Marinus Pharmaceuticals has a one year low of $0.82 and a one year high of $3.25.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. On average, analysts anticipate that Marinus Pharmaceuticals will post ($0.76) EPS for the current year.

Separately, ValuEngine upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 11th.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Insider Buying and Selling by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.